Abbott Laboratories (ABT) Net Profit Margin: 13.91%
Is Abbott Laboratories’s net profit margin high or low?
Abbott Laboratories's net profit margin of 13.91% is 21% below its 5-year average of 17.71%, near the low end of its 5-year range (12.99%–31.95%).
The net profit margin for Abbott Laboratories (ABT) is 13.91% as of Wednesday, June 10, 2026. It is below its 12-month average by 40.39% (23.34%).
ABT Net Profit Margin Chart
ABT Average Net Profit Margin Chart
ABT Current vs Average Net Profit Margin Chart
ABT Net Profit Margin Metrics
NET PROFIT MARGIN
13.91%
NET PROFIT MARGIN AVG TTM
23.34%
NET PROFIT MARGIN AVG 3Y
19.20%
NET PROFIT MARGIN AVG 5Y
17.71%
NET PROFIT MARGIN AVG 10Y
14.15%
NET PROFIT MARGIN AVG 15Y
13.69%
NET PROFIT MARGIN AVG 20Y
13.85%
CURRENT VS TTM AVG
-40.39%
CURRENT VS 3Y AVG
-27.57%
CURRENT VS 5Y AVG
-21.43%
CURRENT VS 10Y AVG
-1.70%
CURRENT VS 15Y AVG
+1.63%
CURRENT VS 20Y AVG
+0.43%
ABT Competitors' Net Profit Margin
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Abbott Laboratories (ABT) | — | 13.91% | 23.34% | 19.20% | 17.71% |
| Gilead Sciences, Inc. (GILD) | $151.21B | 30.99% | 15.29% | 17.07% | 15.27% |
| Intuitive Surgical, Inc. (ISRG) | $146.44B | 28.15% | 28.09% | 25.67% | 26.14% |
| Pfizer Inc. (PFE) | $146.36B | 11.83% | 12.51% | 14.97% | 18.18% |
| Danaher Corporation (DHR) | $130.25B | 14.89% | 15.52% | 19.51% | 19.37% |
| Thermo Fisher Scientific Inc. (TMO) | $179.45B | 15.18% | 14.95% | 14.84% | 16.47% |
| Amgen Inc. (AMGN) | $183.75B | 20.95% | 16.61% | 20.49% | 22.20% |
| CVS Health Corporation (CVS) | $125.16B | 0.72% | 0.84% | 1.34% | 1.79% |
| Bristol-Myers Squibb Company (BMY) | $114.14B | 15.01% | -1.95% | 6.91% | 3.59% |
| Vertex Pharmaceuticals Incorporated (VRTX) | $110.77B | 35.40% | 13.94% | 25.44% | 29.40% |
Margin Comparison
Operating Margin
18.2%
Net Profit Margin
13.9%
Abbott Laboratories Net Profit Margin Formula & Definition
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Abbott Laboratories Net Profit Margin FAQ
- What is the net profit margin for Abbott Laboratories (ABT)?
- The net profit margin for ABT stock is 13.91%.
- Is Abbott Laboratories's net profit margin high or low?
- Abbott Laboratories's net profit margin of 13.91% is 21% below its 5-year average of 17.71%, near the low end of its 5-year range (12.99%–31.95%).
- What is the TTM average net profit margin for Abbott Laboratories (ABT)?
- The TTM average net profit margin for ABT stock is 23.34%.
- What is the 3Y average net profit margin for Abbott Laboratories (ABT)?
- The 3Y average net profit margin for ABT stock is 19.20%.
- What is the 5Y average net profit margin for Abbott Laboratories (ABT)?
- The 5Y average net profit margin for ABT stock is 17.71%.
- What is the 10Y average net profit margin for Abbott Laboratories (ABT)?
- The 10Y average net profit margin for ABT stock is 14.15%.
- What is the 15Y average net profit margin for Abbott Laboratories (ABT)?
- The 15Y average net profit margin for ABT stock is 13.69%.
- What is the 20Y average net profit margin for Abbott Laboratories (ABT)?
- The 20Y average net profit margin for ABT stock is 13.85%.
Abbott Laboratories Net Profit Margin History
| DATE | NET PROFIT MARGIN |
|---|---|
| 2025-12-31 | 14.72% |
| 2024-12-31 | 31.95% |
| 2023-12-31 | 14.27% |
| 2022-12-31 | 15.88% |
| 2021-12-31 | 16.42% |
| 2020-12-31 | 12.99% |
| 2019-12-31 | 11.56% |
| 2018-12-31 | 7.74% |
| 2017-12-31 | 1.74% |
| 2016-12-31 | 6.71% |
| 2015-12-31 | 21.68% |
| 2014-12-31 | 11.28% |
| 2013-12-31 | 11.79% |
| 2012-12-31 | 14.95% |
| 2011-12-31 | 12.17% |
| 2010-12-31 | 13.15% |
| 2009-12-31 | 18.68% |
| 2008-12-31 | 16.53% |
| 2007-12-31 | 13.92% |
| 2006-12-31 | 7.64% |
| 2005-12-31 | 15.10% |
| 2004-12-31 | 16.44% |
| 2003-12-31 | 13.99% |
| 2002-12-31 | 15.80% |
| 2001-12-31 | 9.52% |
| 2000-12-31 | 20.27% |
| 1999-12-31 | 18.56% |
| 1998-12-31 | 18.71% |
| 1997-12-31 | 17.50% |
| 1996-12-31 | 17.09% |
Related Metrics
About Abbott Laboratories
Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Robert Ford